Sovargen

Sovargen is a South Korean biotechnology firm established in 2018, concentrating on the development of therapeutics for intractable neurological disorders. The company emerged from research conducted at the Korea Advanced Institute of Science and Technology (KAIST) by Professor Jeong Ho Lee, a distinguished figure in the neuroscience of rare developmental brain diseases. Professor Lee, who serves as Vice President and Chief Scientific Officer, brings a deep background in neuropharmacology and has been recognized for his work on genomic variations in epilepsy and brain tumors. The company is led by co-Presidents & CEOs BT Kim and Cheolwon Park, who contribute extensive experience from the life sciences, biopharmaceutical, and business development sectors.

The company's core strategy revolves around developing treatments for central nervous system (CNS) diseases caused by brain somatic mosaicism, where a fraction of brain cells contains genetic mutations. Sovargen utilizes a proprietary technology platform for this purpose, which includes SovarIN™ for target discovery, SovarON™ for antisense oligonucleotide (ASO) drug discovery and optimization, and SovarUP™ for validation using disease-specific animal models and human organoid systems. This focus on ASO and RNA therapeutics allows the company to pursue what are often considered undruggable targets within the CNS. Its business model appears to be centered on in-house research and development, funded by venture capital, combined with strategic partnerships and licensing agreements to bring therapies to market. The company has successfully raised significant capital, including a Series A round, to advance its pipeline.

A key part of Sovargen's portfolio is its work on conditions linked to the overactivation of the mTOR pathway. In a significant milestone, Sovargen entered into a licensing agreement with Kazia Therapeutics in March 2024 to develop and commercialize paxalisib for intractable epilepsy in focal cortical dysplasia type 2 (FCD T2) and tuberous sclerosis complex (TSC). This agreement, valued at up to \$20.5 million plus royalties, grants Sovargen worldwide rights (excluding greater China) to develop the brain-penetrant PI3K/mTOR inhibitor for these specific rare diseases, for which there are high unmet medical needs. A Phase 2 clinical trial was anticipated to begin in the latter half of 2024. The company actively seeks global partnerships to enhance its capabilities in areas like bioinformatics, drug delivery systems to cross the blood-brain barrier, and the development of new disease models.

Keywords: neurotherapeutics, RNA therapeutics, antisense oligonucleotide, ASO, central nervous system disorders, rare neurological diseases, somatic mosaicism, drug discovery, focal cortical dysplasia, tuberous sclerosis complex, mTOR pathway, epilepsy treatment, KAIST spin-off, Jeong Ho Lee, brain somatic mutations, paxalisib, gene therapy, neuropharmacology, biotechnology, clinical trials